The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk.

Sone T, Ito M, Fukunaga M, Tomomitsu T, Sugimoto T, Shiraki M, Yoshimura T, Nakamura T

Bone13 Apr 2014Cited by 11 (Europe PMC)

PMID24727160DOI10.1016/j.bone.2014.04.004PepBankPUB-24727160

Publisher page PubMedAsk about this study

Summary

Weekly administration of teriparatide has been shown to reduce the risk of vertebral and non-vertebral fractures in patients with osteoporosis at higher fracture risk in Japan. However, its efficacy for hip fracture has not been established. To gain insight into the effect of weekly teriparatide on the hip, hip structural analysis (HSA) based on dual-energy X-ray absorptiometry (DXA) was performed using the data of 209 postmenopausal osteoporotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled trial assessing the effects of once-weekly 56.5 μg teriparatide for 72 weeks. The DXA scans, obtained at baseline, 48 weeks and 72 weeks, were analyzed to extract bone mineral density (BMD) and cross-sectional geometrical indices at the narrowest point on the neck (NN), the intertrochanteric region (IT), and the proximal shaft. Compared with placebo after 72 weeks, the teriparatide group showed significantly higher BMD, average cortical thickness, bone cross-sectional area, and section modulus, and lower buckling ratio at both the NN and IT regions. No significant expansion of periosteal diameter was observed at these regions. There were no significant differences in BMD and HSA indices at the shaft region. The results indicate that overall structural strength in the proximal femur increased compared to placebo, suggesting that once-weekly teriparatide effectively reverses changes in hip geometry and strength with aging.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide increased BMD at the femoral neck and intertrochanteric region versus placebo.
In plain wordsIn women with osteoporosis, teriparatide increased hip BMD versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck and intertrochanteric BMD
Study
n = 209
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo after 72 weeks, the teriparatide group showed significantly higher BMD, average cortical thickness, bone cross-sectional area, and section modulus, and lower buckling ratio at both the NN and IT regions.
1 context sentence(design, population, supporting numbers)
Summary · context
209 postmenopausal osteoporotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled trial assessing the effects of once-weekly 56.5 μg teriparatide for 72 weeks.
Show in the study text Report a problemFND-2472716001
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide increased average cortical thickness at both hip regions versus placebo.
In plain wordsIn women with osteoporosis, teriparatide increased cortical thickness at both hip regions versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAverage cortical thickness
Study
n = 209
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo after 72 weeks, the teriparatide group showed significantly higher BMD, average cortical thickness, bone cross-sectional area, and section modulus, and lower buckling ratio at both the NN and IT regions.
1 context sentence(design, population, supporting numbers)
Summary · context
209 postmenopausal osteoporotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled trial assessing the effects of once-weekly 56.5 μg teriparatide for 72 weeks.
Show in the study text Report a problemFND-2472716002
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide increased bone cross-sectional area at both hip regions versus placebo.
In plain wordsIn women with osteoporosis, teriparatide increased bone cross-sectional area at both hip regions versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone cross-sectional area
Study
n = 209
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo after 72 weeks, the teriparatide group showed significantly higher BMD, average cortical thickness, bone cross-sectional area, and section modulus, and lower buckling ratio at both the NN and IT regions.
1 context sentence(design, population, supporting numbers)
Summary · context
209 postmenopausal osteoporotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled trial assessing the effects of once-weekly 56.5 μg teriparatide for 72 weeks.
Show in the study text Report a problemFND-2472716003
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide increased section modulus at both hip regions versus placebo.
In plain wordsIn women with osteoporosis, teriparatide increased section modulus at both hip regions versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSection modulus
Study
n = 209
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo after 72 weeks, the teriparatide group showed significantly higher BMD, average cortical thickness, bone cross-sectional area, and section modulus, and lower buckling ratio at both the NN and IT regions.
1 context sentence(design, population, supporting numbers)
Summary · context
209 postmenopausal osteoporotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled trial assessing the effects of once-weekly 56.5 μg teriparatide for 72 weeks.
Show in the study text Report a problemFND-2472716004
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide lowered buckling ratio at both hip regions versus placebo.
In plain wordsIn women with osteoporosis, teriparatide lowered buckling ratio at both hip regions versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBuckling ratio
Study
n = 209
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo after 72 weeks, the teriparatide group showed significantly higher BMD, average cortical thickness, bone cross-sectional area, and section modulus, and lower buckling ratio at both the NN and IT regions.
1 context sentence(design, population, supporting numbers)
Summary · context
209 postmenopausal osteoporotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled trial assessing the effects of once-weekly 56.5 μg teriparatide for 72 weeks.
Show in the study text Report a problemFND-2472716005
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis given once-weekly teriparatide, no significant expansion of periosteal diameter was observed at the femoral neck or intertrochanteric region.
In plain wordsIn women with osteoporosis on weekly teriparatide, no significant widening of the bone's outer diameter was seen at either hip region.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePeriosteal diameter
Study
n = 209
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
No significant expansion of periosteal diameter was observed at these regions.
1 context sentence(design, population, supporting numbers)
Summary · context
209 postmenopausal osteoporotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled trial assessing the effects of once-weekly 56.5 μg teriparatide for 72 weeks.
Show in the study text Report a problemFND-2472716006
07HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, shaft BMD did not differ significantly between teriparatide and placebo.
In plain wordsIn women with osteoporosis, shaft BMD did not differ significantly between teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeShaft BMD
Study
n = 209
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
There were no significant differences in BMD and HSA indices at the shaft region.
1 context sentence(design, population, supporting numbers)
Summary · context
209 postmenopausal osteoporotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled trial assessing the effects of once-weekly 56.5 μg teriparatide for 72 weeks.
Show in the study text Report a problemFND-2472716007
08HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, shaft HSA indices did not differ significantly between teriparatide and placebo.
In plain wordsIn women with osteoporosis, shaft structural indices did not differ significantly between teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeShaft structural indices
Study
n = 209
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
There were no significant differences in BMD and HSA indices at the shaft region.
1 context sentence(design, population, supporting numbers)
Summary · context
209 postmenopausal osteoporotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled trial assessing the effects of once-weekly 56.5 μg teriparatide for 72 weeks.
Show in the study text Report a problemFND-2472716008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.